Gilead and Merck's Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials

Event summary

  • Gilead and Merck's Phase 3 ISLEND-1 and ISLEND-2 trials met primary efficacy endpoints at Week 48 for their once-weekly HIV treatment regimen islatravir/lenacapavir (ISL/LEN).
  • The trials showed ISL/LEN was statistically non-inferior to BIKTARVY in ISLEND-1 and to standard of care daily oral antiretroviral therapy regimens in ISLEND-2.
  • The safety profile of ISL/LEN was generally comparable to the comparator regimens, with no new safety concerns identified.
  • Gilead and Merck plan to file the Phase 3 data with regulatory authorities globally and submit detailed findings for presentation at a future scientific congress.

The big picture

The positive Phase 3 results for Gilead and Merck's once-weekly HIV treatment regimen represent a significant step forward in the quest for less frequent dosing options for HIV patients. This innovation could potentially reshape the HIV treatment landscape, offering more flexibility and discretion for patients. The collaboration between Gilead and Merck underscores the industry's focus on advancing long-acting therapies to improve patient outcomes and adherence.

What we're watching

Regulatory Approval
The pace at which Gilead and Merck secure regulatory approvals for ISL/LEN will determine its market entry timeline and competitive positioning.
Market Adoption
Whether the once-weekly dosing regimen of ISL/LEN can drive patient preference and adoption, potentially reshaping the HIV treatment landscape.
Competitive Dynamics
How ISL/LEN's efficacy and safety profile will compare against existing HIV treatments, particularly BIKTARVY, in the long-term.